Kidney Cancer

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

By

Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

By

Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.

Smoking-related Cancer Deaths Highest in Southern United States

Smoking-related Cancer Deaths Highest in Southern United States

By

Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.

New Class of Drugs Shows Promise Against Kidney Cancer

New Class of Drugs Shows Promise Against Kidney Cancer

By

A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

By

Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).

Double Autologous HCT Improves Outcomes in High-risk Pediatric Neuroblastoma

By

Adding a second autologous hematopoietic cell transplantation (HCT) to standard therapy improves outcomes for pediatric patients with high-risk neuroblastoma.

Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used

By

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.

Drug-Resistant Cancer May Be Combatted With New Generation mTOR Inhibitors

By

A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.

Genetic Differences Explain Survival Disparity in African Americans With Kidney Cancer

By

Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

By

Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.

Progression-free Survival in Advanced Renal Cell Carcinoma Is Improved With Cabozantinib

By

Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.

Nivolumab  Now FDA Approved for Advanced RCC

Nivolumab Now FDA Approved for Advanced RCC

This newly approved drug operates by targeting the PD-1/PD-L1 cellular pathway.

Diabetes Linked to Worse Survival in Renal Cell Carcinoma

Diabetes Linked to Worse Survival in Renal Cell Carcinoma

For patients with diabetes, poor glycemic control is linked to higher risk of postoperative progression.

Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma

Nivolumab Indications Extended to Include Advanced Renal Cell Carcinoma

By

The FDA extended indications for nivolumab (Opdivo) to include treatment of advanced (metastatic) renal cell carcinoma (RCC).

Cause of a Childhood Kidney Cancer Is a Previously Unrecognized Role of a Known Gene

Cause of a Childhood Kidney Cancer Is a Previously Unrecognized Role of a Known Gene

By

Genetic mutations in the REST gene have been shown to cause Wilms tumor, a rare kidney cancer that occurs in children. The findings identified mutations in the REST gene in 16 children with Wilms tumor.

Specific Genetic Alterations Observed in Papillary Renal-Cell Carcinomas

Specific Genetic Alterations Observed in Papillary Renal-Cell Carcinomas

Type 1 and type 2 carcinomas are characterized by specific genetic alterations; type 2 consists of at least three subtypes.

Forms of Meat Preparation May Increase Renal Cell Carcinoma Risk

Forms of Meat Preparation May Increase Renal Cell Carcinoma Risk

By

A recent study has linked an increased risk of kidney cancer to certain meat-cooking mutagens.

Model Developed for Predicting Toxicity-related Treatment Discontinuation in mRCC

Model Developed for Predicting Toxicity-related Treatment Discontinuation in mRCC

By

Independent risk factors for toxicity-related treatment discontinuation (TrTD) in patients with metastatic renal cell carcinoma (mRCC).

Questionnaire Effective in Assessing Adverse Events in Renal Cell Carcinoma

Questionnaire Effective in Assessing Adverse Events in Renal Cell Carcinoma

By

Frequent adverse events experienced by patients receiving tyrosine kinase inhibitors are hand-foot syndrome and mucositis/stomatitis.

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

Risk of Cardiovascular Events Higher After Antiangiogenic Therapy for RCC in Persons Older Than 65 Years

Sunitinib and sorafenib may be associated with an increased risk of cardiovascular events in older patients with renal cell carcinoma (RCC).

New Drug Improves Outcome in Treatment Resistant Kidney Cancer

New Drug Improves Outcome in Treatment Resistant Kidney Cancer

A new drug is proven more effective than standard therapies for advanced kidney cancer in patients with demonstrated drug resistance.

Novel Immunotherapy Shows Promise Against Advanced Renal Cancer

Novel Immunotherapy Shows Promise Against Advanced Renal Cancer

In new clinical trial, Nivolumab raised median survival for patients with advanced renal-cell carcinoma.

Patient Disparity in Trials vs Clinic Raises Doubts on Kidney Cancer Drug Efficacy

Patient Disparity in Trials vs Clinic Raises Doubts on Kidney Cancer Drug Efficacy

Four drugs that were recently approved by the FDA for the treatment of kidney cancer are being doubted for their clinical application.

Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma

Sunitinib Plus Gemcitabine Active in Sarcomatoid, Poor-Risk Renal Cell Carcinoma

Antiangiogenic therapy and cytotoxic therapy are an active and well-tolerated combination for aggressive renal cell carcinoma (RCC).

Robotic Inferior Vena Cava (IVC) Thrombectomy Successfully Removes Thrombus Associated With Kidney Cancer

By

Inferior vena cava (IVC) thrombectomy is typically is performed via a large open incision, but recently the procedure was successfully performed robotically, using only seven small incisions.

Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer

Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer

The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC).

Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy

Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy

Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy appear to have low risk for renal dysfunction.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs